Growing Client Base Qureight has recently expanded its client portfolio by signing Mediar Therapeutics for systemic sclerosis trials, indicating opportunities to sell its AI-powered imaging solutions to other biopharmaceutical companies engaged in lung and heart disease research.

Advanced AI Development With ongoing development of deep learning AI imaging models and participation in industry conferences, Qureight is positioning itself as an innovative leader, creating opportunities to collaborate on or license cutting-edge imaging analytics for clinical trials.

Leadership Expansion Recent executive hires, including a Chief Operating Officer and a Chief Medical Officer, suggest strategic growth and increased focus on customer engagement, providing avenues for sales teams to target decision-makers and tailor solutions for enterprise clients.

Market Presence Qureight actively participates in international conferences such as ATS 2025 and 2026, showcasing its technology to key industry stakeholders and opening channels for networking, partnerships, and enterprise sales opportunities in respiratory and cardiovascular research.

Funding and Revenue With revenues between 1M to 10M and ongoing product development, Qureight presents a compelling opportunity for strategic investment, partnership, or increased usage of its AI-driven imaging platform as the company continues to grow its market share.